[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"mature-b-cell-lymphoma\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:mature-b-cell-lymphoma":24},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,42,70],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":22,"conditions":23,"keywords":25,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":30,"lastUpdatePostDateStruct":31,"startDateStruct":34,"completionDateStruct":36,"leadSponsor":38,"locationsCount":41},"100633371","a-real-world-study-of-pirtobrutinib-in-cbtki-resistantintolerant-mature-b-cell-lymphoma-100633371",false,"NCT07525817","A Real-World Study of Pirtobrutinib in cBTKi-Resistant\u002FIntolerant Mature B-Cell Lymphoma","A Prospective, Multicenter, Real-World Study of Pirtobrutinib in Patients With Mature B-Cell Lymphoma Resistant or Intolerant to Covalent Bruton Tyrosine Kinase Inhibitors","Inclusion Criteria:\n\n* Age ≥18 years;\n* Histopathological confirmation of mature B-cell lymphoma, primarily including CLL\u002FSLL, MCL, FL, MZL, WM\u002FLPL, etc.;\n* Disease progression and\u002For intolerance after prior treatment with ≥1 cBTKi (including ibrutinib, ibrutinib, zanubrutinib, or acitinib);\n* ECOG PS 0-2;\n* Adequate liver and kidney function: the following criteria must be met simultaneously: 1) AST and ALT ≤ 3×ULN; 2) Total bilirubin ≤ 1.5×ULN; 3) Creatinine clearance rate ≥ 30 mL\u002Fmin;\n* Participants must be voluntary and capable of completing the study procedures and follow-up examinations;\n* Informed consent must be obtained voluntarily prior to screening.\n\nExclusion Criteria:\n\n* Patients with known allergic reactions to any component or excipient of piteutinib;\n* Patients concurrently participating in other clinical studies;\n* A history of clinically significant, uncontrolled cardiac,\n* Cardiovascular disease, or myocardial infarction within 6 months prior to planned initiation of piteutinib therapy;\n* Uncontrolled systemic bacterial, viral, fungal, or parasitic infections; current use of potent CYP3A4 inhibitors or inducers and\u002For potent P-gp inhibitors;\n* Positive human immunodeficiency virus (HIV) testing;\n* Active hepatitis B or C: 1) Patients with positive hepatitis B virus (HBV) DNA testing and controlled disease status may be enrolled with investigator approval. For HBV DNA-positive patients, concurrent antiviral therapy is required. 2) Patients with prior hepatitis C virus (HCV) infection history who have completed antiviral therapy with viral loads below the quantitative limit may be enrolled;\n* Based on the investigator's assessment, participants may be unable to complete all study protocol requirements, including follow-up visits, and\u002For adhere to all study procedures;\n* A history of other clinically significant diseases or comorbidities; and any safety risks or potential interference with study completion as evaluated by investigators.","ALL","18 Years",{"count":19,"type":20},40,"ESTIMATED","OBSERVATIONAL","This is a prospective, multicenter, real-world study to evaluate the efficacy and safety of pirtobrutinib in patients with mature B-cell lymphoma who are resistant or intolerant to prior covalent BTK inhibitors. The primary endpoint is overall response rate (ORR). Secondary endpoints include best overall response (BOR), duration of response (DOR), progression-free survival (PFS), overall survival (OS), and safety. A total of 40 patients will be enrolled across 8 centers in China.",[24],"Mature B-Cell Lymphoma",[26,27,28],"Pirtobrutinib","Covalent BTK inhibitor","Mature B-cell lymphoma","NOT_YET_RECRUITING","2026-04-07",{"date":32,"type":33},"2026-04-13","ACTUAL",{"date":35,"type":20},"2026-04-01",{"date":37,"type":20},"2028-12-31",{"name":39,"class":40},"Ou Bai, MD\u002FPHD","OTHER",1,{"id":43,"slug":44,"hasResults":11,"nctId":45,"briefTitle":46,"officialTitle":47,"acronym":4,"eligibilityCriteria":48,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":49,"targetDuration":4,"studyType":51,"phases":52,"briefSummary":54,"conditions":55,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":61,"lastUpdatePostDateStruct":62,"startDateStruct":64,"completionDateStruct":66,"leadSponsor":68,"locationsCount":41},"100601669","phase-1-rn1201injection-for-relapsedrefractory-cd19bcma-hematologic-malignancies-100601669","NCT07113496","RN1201injection for Relapsed\u002FRefractory CD19+\u002FBCMA+ Hematologic Malignancies","An Exploratory Clinical Study on the Safety and Efficacy of Allogeneic CAR-T Cell (RN1201) for Relapsed\u002FRefractory CD19+\u002FBCMA+ Hematologic Malignancies","Inclusion Criteria\n\n1. Voluntary participation with signed informed consent.\n2. Pathologically confirmed CD19-positive and\u002For B-cell maturation antigen (BCMA)-positive hematologic malignancy according to the WHO 2017 classification, including but not limited to multiple myeloma, B-cell acute lymphoblastic leukemia (B-ALL), mature B-cell lymphomas, and plasmablastic lymphoma.\n3. Relapsed\u002Frefractory disease defined as failure to achieve complete remission after standard therapy, or relapse after an initial response during treatment or follow-up.\n4. Measurable disease required:\n\n   1. For B-ALL: persistent minimal residual disease (MRD) positivity despite hematologic remission.\n   2. For lymphoma: at least one measurable lesion ≥1.5 cm in longest diameter per IWG revised criteria.\n   3. For multiple myeloma: positive immunofixation electrophoresis or presence of extramedullary disease.\n5. Age ≥18 years; both sexes eligible.\n6. Expected survival ≥12 weeks.\n7. Adequate organ function (exceptions for disease-related impairment are at the investigator's discretion):\n\n   1. Total bilirubin \\\u003C2× upper limit of normal (ULN); serum creatinine \\\u003CULN; ALT and AST \\\u003C3× ULN.\n   2. Absolute neutrophil count ≥0.5×10⁹\u002FL; platelets ≥20×10⁹\u002FL (no requirement if marrow involvement is documented).\n   3. Eastern Cooperative Oncology Group (ECOG) performance status 0-3.\n   4. Left ventricular ejection fraction (LVEF) ≥50%.\n\nExclusion Criteria\n\n1. Known hypersensitivity, allergy, intolerance, or contraindication to CD19\u002FBCMA-UCAR-T or any study drugs (fludarabine, cyclophosphamide, tocilizumab).\n2. Genetic syndromes: Fanconi, Kostmann, Shwachman, or any documented bone-marrow failure syndrome.\n3. Active or uncontrolled infection requiring IV antibiotics; evidence of severe active infection.\n4. NYHA Class III or IV heart failure (unless clearly secondary to the underlying malignancy).\n5. Central Nervous System (CNS) disorders unrelated to the primary hematologic malignancy.\n6. Prior malignancy except adequately treated carcinoma in situ of skin, cervix, lung, or other non-active tumors.\n7. Significant bleeding diathesis (e.g., gastrointestinal (GI) bleeding, coagulopathy, hypersplenism).\n8. History of significant cardiac disease within the past 3 months that, in the investigator's judgment, renders the patient unable to tolerate study participation..\n9. Pregnancy, lactation, or planned pregnancy within 6 months.\n10. Any condition that, in the investigator's opinion, may increase risk or interfere with study results.",{"count":50,"type":20},27,"INTERVENTIONAL",[53],"PHASE1","This single-arm, dose-escalation exploratory trial evaluates the safety and efficacy of Allogeneic CAR-T (UCAR-T) cell therapy in patients with relapsed or refractory CD19+\u002FBCMA+ hematologic malignancies, including those with minimal residual disease (MRD). Eligible patients will receive lymphodepletion followed by a single infusion of UCAR-T cells, either post-transplant or without transplantation depending on disease status. The trial assesses overall response and disease control rates, treatment-emergent adverse events, and in vivo behavior of UCAR-T cells.",[56,57,58,59,60,24],"Relapsed or Refractory B-cell Hematologic Malignancies","B-cell Acute Lymphoblastic Leukemia (B-ALL)","Multiple Myeloma (MM)","Plasmablastic Lymphoma","Relapsed or Refractory CD19+\u002FBCMA+ Hematologic Malignancies","2025-08-08",{"date":63,"type":33},"2025-08-13",{"date":65,"type":20},"2025-08",{"date":67,"type":20},"2027-12",{"name":69,"class":40},"The First Affiliated Hospital with Nanjing Medical University",{"id":71,"slug":72,"hasResults":11,"nctId":73,"briefTitle":74,"officialTitle":75,"acronym":4,"eligibilityCriteria":76,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":77,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":79,"conditions":80,"keywords":4,"overallStatus":81,"whyStopped":4,"lastUpdateSubmitDate":82,"lastUpdatePostDateStruct":83,"startDateStruct":85,"completionDateStruct":87,"leadSponsor":89,"locationsCount":41},"100369291","cell-free-dna-in-mature-b-cell-lymphoma-100369291","NCT04088422","Cell Free DNA in Mature B-cell Lymphoma","Prospective, Observational Study on Cell Free DNA Genotyping as a Tool to Inform Mature B-cell Lymphoma Management","Inclusion Criteria:\n\n* Documented diagnosis of mature B-cell tumor according to WHO 2008 criteria\n* 18 years or older\n\nExclusion Criteria:\n\n* Chemotherapy before\n* Other tumors",{"count":78,"type":20},320,"The purpose of this study is to assess whether plasma cell free DNA is an accurate tool that can early and dynamically inform on treatment outcome and an accessible source of tumor DNA to track tumor clonal evolution.",[24],"RECRUITING","2023-02-23",{"date":84,"type":33},"2023-02-24",{"date":86,"type":33},"2022-09-28",{"date":88,"type":20},"2026-12",{"name":90,"class":40},"Ruijin Hospital"]